Prognostic indicators for early discontinuation of risperidone long-acting injection

International Clinical Psychopharmacology

Volumn 19, Issue 4, 2004, Pages 233-239

  Patel, Maxine X ^a   Young, Corina ^b   Samele, Chiara ^a   Taylor, David M ^b   David, Anthony S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atypical antipsychotics; Follow up study; Health technology assessment; Long acting injection; Psychotic disorders; Treatment adherence

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MENTAL PATIENT; PHARMACY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOSIS; RETROSPECTIVE STUDY; SAMPLING; SOCIAL ASPECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 3142624607     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000130231.50006.da     Document Type: Article

References (39)

1. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E (2003). Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63:495-512.
2. BNF (2003). British Medical Association and Royal Pharmaceutical Society of Great Britain British National Formulary No. 45. London: Royal Pharmaceutical Society, British Medical Association.
3. Chakos M, Lieberman J, Hoffman E, Bradfor D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526.
4. Chue P, Eerdekens M, Augustyns I, Lacheux B, Molcan P, Eriksson H, et al. (2002). Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophr Res 53 (suppl 3):174.
5. Conte G, Ferrari R, Guarneri L, Alessandro C, Sacchetti E (1996). Reducing the 'revolving door' phenomenon. Am J Psychiatry 153:1512.
6. Cramer JA, Rosenheck R (1998). Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196-201.
7. Davis JM, Matalon L, Watanabe MD, Blake L (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47:741-773.
8. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-M, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
9. Fulop N, Allen P, Clarke A, Black N (2001). Issues in studying the organisation and delivery of health services. In: Fulop N, Allen P, Clarke A, Back N (editors): Studying the Organisation and Delivery of Health Services: Research Methods. London: Routledge, pp. 1-23.
10. Heyscue BE, Levin GM, Merrick JP (1998). Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 49: 1232-1234.
11. ICD-10 (1992). The International Classification of Diseases, Version 10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organisation.
12. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
13. Kemp R, David A (1997). Insight and compliance. In: Blackwell B (editor): Treatment Compliance and the Therapeutic Alliance in Serious Mental Illness. The Netherlands: Harwood Academic Publishers, pp. 61-84.
14. Kerwin R (2003). Where do depot injections fit in schizophrenia management? Progr Neurol Psychiatry 7:6-7.
15. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63:892-907.
16. Lambert T, Brennan A, Castle D, Kelly DL, Conley RR (2003). Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract 9:252-260.
17. Lindstrom E, Bingefors K (2000). Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 18:106-124.
18. Meltzer HY (1992). Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18:515-542.
19. National Institute for Clinical Excellence (NICE) (2002). Technology Appraisal Guidance No. 43: Guidance on the Use of New (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. http://www.nice.org.uk/pdf/ ANTIPSYCHOTICfinalguidance.pdf.
20. NHS Management Executive (1992). Assessing the Effects of Health Technologies. London: Department of Health.
21. Office for National Statistics (2001). http://www.statistics.gov.uk/ census2001.
22. Patel MX, David AS (2004). Why aren't depots prescribed more often, and what can be done about it? Adv Psychiatr Treatment 00:000-000.
23. Patel M, Nikolaou V, David AS (2003a). Eliciting psychiatrists' beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract 7:117-120.
24. Patel MX, Nikolaou V, David AS (2003b). Psychiatrists attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33:83-89.
25. Robert G, Stevens A, Gabbay J (1998). Horizon scanning: early identification of new health care technologies. In: Black N, Brazier J, Fitzpatrick R, Reeves B (editors): Health Services Research: A Guide to Best Practice. London: BMJ Books, pp. 215-225.
26. Stevens A, Milne R, Black N (1998). Researching health services. In: Black N, Brazier J, Fitzpatrick R, Reeves B (editors): Health Services Research: A Guide to Best Practice. London: BMJ Books, pp. 1-11.
27. Tattan TMG, Creed FH (2001). Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 27:149-155.
28. Taylor D, Mir S, Mace S, Hogman G (1999). Is Cost a Factor - II? A Survey of Psychiatrists and Health Authorities to Determine the Factors Influencing the Prescribing and Funding of Atypical Antipsychotics. London: National Schizophrenia Fellowship.
29. Taylor D, Young C, Paton C (2003a). Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 64: 30-34.
30. Taylor D, Paton C, Kerwin R (2003b). The South London, Maudsley NHS Trust Prescribing Guidelines, 7th edn. London: Martin Dunitz.
31. Thieda P, Beard S, Richter A, Kane J (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54:508-516.
32. United Kingdom Psychiatric Pharmacy Group (2002). http://www.ukppg.org. uk/ 02-09-risperidone-consta-1.html.
33. Walburn J, Gray R, Gournay K, Quraishi S, David AS (2001). A systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300-307.
34. Weiden PJ, Olfson M (1995). Cost of relapse in schizophrenia. Schizophr Bull 21:419-429.
35. Weiden P, Glazer W (1997). Assessment and treatment selection for 'revolving door' inpatients with schizophrenia. Psychiatr Quart 68:377-392.
36. Whiskey E, Wykes T, Duncan-McConnell D, Haworth E, Walsh N, Hastilow S (2003). Continuation of clozapine treatment: practice makes perfect. Psychiatr Bull 27:211-213.
37. Wistedt B (1995). How does the psychiatric patient feel about depot treatment, compulsion or help? Nordic J Psychiatry 49 (suppl 35):41-46.
38. Young JL, Zonana HV, Shepler L (1986). Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 14:105-122.
39. Young JL, Spitz RT, Hillbrand M, Danieri G (1999). Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. J Am Acad Psychiatry Law 27:426-444.